Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

Norfolk entrepreneur Tait Pollack from Norwich has credited sleep for saving his life after recovering from a life-threating illness following ...

AstraZeneca (NASDAQ:AZN ... and label expansions for Tagrisso and Imfinzi in the second half of the previous year. It is equally critical to discuss the successes and failures in the ...

The second dose of Oxford-AstraZeneca COVID-19 vaccine will be administered from Wednesday (April 28), says State Minister of Production, Supply, and Regulation of Pharmaceuticals Prof. Channa ...

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...

WASHINGTON: The Central Intelligence Agency on Saturday shifted its official stance on the origin of COVID-19, saying that it ...

The U.S. government has selected the second batch of drugs up for Medicare ... Bristol Myers Squibb, AstraZeneca, GSK and other companies. Novo’s booming semaglutide franchise for diabetes ...

The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.